Search papers, labs, and topics across Lattice.
This paper introduces the Nanotechnology Molecular Optimization (NMO) Benchmark, designed to enhance generative molecular design by integrating quantum simulations and addressing the limitations of traditional drug-like property benchmarks. The NMO Benchmark serves as both a rigorous evaluation platform for machine learning models and a catalyst for scientific discovery in nanotechnology, emphasizing the importance of scientific utility over mere leaderboard performance. Key findings reveal that simpler optimization methods can outperform more complex approaches on NMO tasks, highlighting critical components for effective molecular optimization and uncovering new structural motifs relevant to the field.
Simpler molecular optimization methods can outperform advanced techniques in tackling the NMO Benchmark, revealing new insights for nanotechnology research.
Generative molecular design is shaped by simple proxy benchmarks for drug-like properties and models pretrained on large pharmaceutical datasets. This combination yields strong benchmark metrics but limits transferability to domains structurally distinct from drug discovery. To overcome this limitation and drive discovery toward real, scientifically grounded targets, we introduce the Nanotechnology Molecular Optimization (NMO) Benchmark, which bridges machine learning (ML) and quantum materials science. NMO acts simultaneously as a rigorous testbed for the ML community and a discovery engine for nanotechnology research. The suite replaces proxy oracles with quantum simulations and introduces strict protocols that prioritize scientific utility over leaderboard-oriented overfitting. The physics-based NMO tasks impose hard structural constraints and rugged fitness landscapes, posing fundamentally new requirements on generative models. Notably, advanced molecular optimization methods underperform much simpler approaches on the NMO tasks. We develop a new baseline method identifying the critical components to solve the NMO tasks, including a novel representation for modeling structural constraints and a domain-agnostic pretraining strategy to eliminate pharmaceutical dataset bias. Our results surpass state-of-the-art physical properties and reveal previously unknown structural motifs, offering new insights for the nanotechnology community and demonstrating that ML can drive genuine scientific discovery.
